Respiratory Therapeutics is the Largest Segment Driving the Growth of Pulmonary Drugs Market

The global Pulmonary Drugs Market is estimated to be valued at US$ 3.41 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Pulmonary drugs are beneficial for the treatment of respiratory diseases like asthma, cystic fibrosis, chronic obstructive pulmonary disease and other lung disorders. These drugs help in improving lung function, alleviate symptoms and control airway inflammation.

Market Key Trends:
One of the key trends witnessed in the pulmonary drugs market is the growing preference for nebulized delivery of drugs over conventional methods. Nebulizers offer several advantages like direct delivery of drugs to the lungs, lower drug dosage requirement and better lung deposition. They have emerged as an effective alternative for patients unable to use pressurized metered dose inhalers or dry powder inhalers. Several new drug-device combination products are being launched incorporating nebulized delivery systems.

Market key trends:

The global pulmonary drugs market has been witnessing high growth owing to the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Rising environmental pollution levels, growing geriatric population, and changing lifestyle habits resulting in smoking have been key drivers for the growth of the market. Furthermore, the development and launch of novel biologics and formulations for improved treatment of respiratory disorders is expected to drive the market during the forecast period.

SWOT Analysis

Strength: Wide range of drugs available for treatment of pulmonary diseases. Growing awareness regarding respiratory illnesses.
Weakness: High costs associated with development of novel treatment regimens. Side effects of few drugs discourage compliance.
Opportunity: Rising pollution and urbanization in developing nations present an opportunity. Untapped rural markets yet to adopt pulmonary drugs.
Threats: Patent expiry of blockbuster drugs. Slow regulatory approval process delays market entry.

Key Takeaways

Global Pulmonary Drugs Market Size is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing prevalence of respiratory diseases across both developed and developing nations.

The regional analysis indicates that North America dominated the market in 2023, owing to growing elderly population, favorable reimbursement policies, and strong presence of key players in the region. However, Asia Pacific is anticipated to witness fastest growth during the forecast period due to rising pollution levels, growing healthcare expenditure, and favourable government support.

Key players operating in the pulmonary drugs market are Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited. The market is highly competitive with these players introducing generic versions for drugs losing patents and focusing on development of innovative delivery systems. 

Read More-

8 thoughts on “Respiratory Therapeutics is the Largest Segment Driving the Growth of Pulmonary Drugs Market”

  1. 2023-24英超聯賽萬眾矚目,2023年8月12日開啟了第一場比賽,而接下來的賽事也正如火如荼地進行中。本文統整出英超賽程以及英超賽制等資訊,幫助你更加了解英超,同時也提供英超直播平台,讓你絕對不會錯過每一場精彩賽事。


    英超聯賽(English Premier League,縮寫EPL)由英國最頂尖的20支足球俱樂部參加,賽季通常從8月一直持續到5月,以下帶你來了解英超賽制和其他更詳細的資訊。


    採雙循環制,分主場及作客比賽,每支球隊共進行 38 場賽事。



Leave a Comment